Loading clinical trials...
Loading clinical trials...
Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients
Conditions
Interventions
CREXONT ER
Locations
27
United States
Barrow Neurological Institute
Phoenix, Arizona, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Parkinson's Research Centers of America - Orange County
Aliso Viejo, California, United States
Parkinson's Research Centers of America - Palo Alto
Palo Alto, California, United States
Visionary Investigators Network
Aventura, Florida, United States
Parkinsons Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, United States
Start Date
February 12, 2025
Primary Completion Date
November 1, 2025
Completion Date
August 6, 2026
Last Updated
August 24, 2025
NCT07187843
NCT07545473
NCT07543861
NCT05748028
NCT07495462
NCT04876339
Lead Sponsor
Impax Laboratories, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions